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Abstract.
Objective: To examine the effect of intravesical radiofrequency-induced chemohyperthermia (RF-CHT) in carcinoma in-situ
(CIS) patients overall and split according to previously received therapy.
Methods: CIS patients that underwent an induction and maintenance phase of≥6 RF-CHT instillations, and had either
pathology or cystoscopy plus cytology available at 6 months of follow-up were retrospectively included. Complete response
(CR), recurrences, cystectomy-free rate, overall survival (OS), and adverse events were evaluated. Analysis was performed
for overall, bacillus Calmette-Gue´rin (BCG)-unresponsive, other BCG-treated, and treatment naı¨ve patients.
Results: Patients (n = 150) had a mean of 17.5, 9.2, or 0 previous BCG instillations in the BCG-unresponsive (n = 50), other
BCG-treated (n = 46, missing n = 4), and treatment naı¨ve groups (n = 47, missing n = 3), respectively. After 6 months, a CR
of 46.0%, 71.7%, and 83.0% was found (p < 0.001). Subsequent 2-year recurrence rates were 17.4%, 27.3%, and 12.8%,
respectively. The overall cystectomy-free rate and OS at mean follow-up (35.8 months) were 78.5% and 78.0%, respectively.
These were 71.4% vs. 84.1% vs. 86.7% (cystectomy-free rate, p = 0.006) and 76.0% vs. 69.6% vs. 87.2% (OS, p = 0.06)
for BCG-unresponsive vs. other BCG-treated vs. treatment naı¨ve patients. Progression to muscle-invasive disease was seen
in 13.3% of patients. Patients stopped induction or maintenance RF-CHT instillations due to adverse events in respectively
13.4% and 17.8%.
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Conclusions: Intravesical RF-CHT showed good results in both treatment naı¨ve and BCG-treated CIS patients, avoiding
the need for cystectomy in 78.5% of cases for at least 3 years with a modest risk of progression. Thus, RF-CHT proves an
alternative to cystectomy in selected high-risk patients.
Keywords: Hyperthermia, radiofrequency, urinary bladder neoplasms, intravesical therapy, carcinoma in situ, bacillus
Calmette-Gue´rin
INTRODUCTION
Urothelial cell carcinoma in-situ (CIS) of the uri-
nary bladder is a relatively uncommon finding in
patients with non-muscle-invasive bladder cancer
(NMIBC), with less than 10% of cases having asso-
ciated CIS [1]. However, due to the high number
of patients with bladder cancer and its high recur-
rence rate, urothelial CIS is still associated with a
significant prevalence [2, 3]. Urothelial CIS is a non-
papillary high-grade form of NMIBC. Unlike most
intraepithelial carcinomas in other organs, CIS of
the urinary tract is – with a hazard ratio of 1.46 –
at high risk of progression to muscle-invasive dis-
ease (MIBC), with a subsequent risk of metastasis
and mortality [4, 5]. Without treatment, over 50% of
patients progress to MIBC [6].
To prevent progression to MIBC and facilitate
bladder preservation in patients with CIS, an intensive
intravesical management is advised by the urologi-
cal guidelines [7, 8]. The current gold standard for
CIS consists of full dose bacillus Calmette-Gue´rin
(BCG) immunotherapy in a 3-year induction plus
maintenance scheme according to the SWOG proto-
col [9, 10]. This results in a complete response (CR)
rate of 70–75% after 3 months [11]. However, a sig-
nificant number of patients eventually prove to be
BCG-unresponsive or intolerant [12–15]. Two poten-
tial issues with BCG are the adverse events associated
with this viable, although weakened, mycobacterium,
and the fact that availability of BCG is dependent on
growth of the mycobacterium under highly controlled
circumstances which can be achieved by a limited
number of manufacturers, making BCG susceptible
to scarcity.
Alternative bladder-sparing therapies to replace
BCG immunotherapy are being investigated [16].
An effective option is to combine intravesical
chemotherapy with mild hyperthermia of the bladder
mucosa [17, 18]. A recent randomized clinical trial
evaluated the efficacy of intravesical radiofrequency-
induced chemohyperthermia (RF-CHT) vs. BCG
immunotherapy in intermediate-high risk NMIBC
patients, showing a 2-year recurrence free survival
(RFS) rate of 81.8% and 64.8%, respectively, and a
progression rate of <2% in both groups [19]. How-
ever, this study included only 43 CIS patients who all
were BCG-naı¨ve. A previous exploratory retrospec-
tive study of RF-CHT efficacy in 49 CIS patients, of
which 15 were BCG-naı¨ve, showed a 3-months CR
rate of 92% which remained 51% after 2 years [20].
Nonetheless, evidence on RF-CHT efficacy in CIS
patients is limited, specifically in those who have been
previously treated with BCG. In these patients, RF-
CHT might be considered prior to radical cystectomy
provided that its efficacy is sufficient [21].
We aimed to examine the effect of intravesical RF-
CHT in CIS patients who were either treatment naı¨ve,
or who were previously treated with or unresponsive
to BCG immunotherapy.
PATIENTS AND METHODS
Patient selection
Patients with histologically proven CIS, with or
without coexisting papillary Ta/T1 NMIBC tumor(s),
who had been treated with RF-CHT using mito-
mycin C (MMC) were retrospectively collected from
six international centres between January 2000 and
December 2016. Of these, those who had received≥6
RF-CHT instillations and had either pathology or
the combination of cytology and cystoscopy results
available at 6 months (range 5–9 months) of follow-
up were eligible for the efficacy analysis. Efficacy
analysis was additionally performed separately for
treatment naı¨ve patients, for patients that were BCG-
unresponsive, and for the remaining BCG-treated
group, i.e. patients who were BCG-intolerant or did
not meet the definition of BCG-unresponsive disease
due to late disease recurrence or due to an inadequate
BCG regimen. Treatment naı¨ve patients generally
had received RF-CHT due to unavailability of BCG,
or within a previous different study protocol. BCG-
unresponsive disease was defined as a persistence or
recurrence of CIS after an adequate BCG regimen
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was initiated, or relapse of CIS within 6 months of
their last intravesical treatment with BCG despite an
initial complete response to BCG [16, 22]. An ade-
quate BCG regimen was defined as at least 2 courses
of BCG where the first course (induction) must have
included at least 5 out of 6 weekly treatments and the
second course may have included a re-induction (5
out of 6 treatments) or maintenance of at least 2 out
of 3 treatments.
For evaluation of treatment tolerability all patients
who had received any RF-CHT instillations were
used.
Due to the retrospective nature, no approval of any
ethical committee was needed.
Outcomes
The primary endpoint was CR after 6 months since
start of RF-CHT, defined as absence of CIS, pap-
illary high-grade (HG) tumor, stage T1 tumor, or
extra-vesical evidence of urothelial carcinoma. To be
considered a complete responder, a patient had to
have a negative result as proven by histopathologic
examination or by cystoscopy and urine cytology.
Exceptions to this definition included patients with
only upper tract involvement, or patients with a Ta-
low grade (TaLG) recurrence only since this was
regarded as having a clinical benefit from therapy.
These patients were evaluated as responders.
As secondary end-points, both the 2-year recur-
rence rate and recurrence free survival (RFS) after
CR, as confirmed by pathology or cytology plus cys-
toscopy, were evaluated. Additionally, progression
rate, overall survival (OS), cystectomy-free survival,
and treatment tolerability were assessed at final
follow-up. Progression was defined as development
of MIBC with or without lymph node or distant
metastasis at final follow-up. Treatment tolerability
was evaluated by assessment of the drop-out rate due
to adverse event which could include spasms, urgency
or frequency between or during sessions, or allergic
reactions to the instilled drug.
To investigate whether additional RF-CHT instil-
lations were of value in treatment of CIS, we
also evaluated CR rates after further maintenance
RF-CHT instillations with its associated 2-year recur-
rence rate.
Treatment
Radiofrequency-induced chemohyperthermia was
given using the Synergo® SB-TS 101 system
[18]. This system consists of a 915 MHz intraves-
ical microwave applicator located in a specifically
designed catheter that delivers mild hyperthermia
(40.5 to 44◦C) to the bladder wall via direct non-
ionizing irradiation. Temperatures were monitored by
two urethral and three mucosal thermocouples inte-
grated in the 20 French catheter. To avoid urethral
overheating and disintegration of the chemotherapeu-
tic agent, the solution was continuously recirculated
and cooled. Typically, MMC was used in a dose of
40 mg/50 ml. The instilled solution was replaced by a
fresh identical solution after 30 min (a total of 80 mg
MMC in 1 h). Patients were treated weekly for 4 to
8 weeks depending on the planned induction sched-
ule, which was followed by maintenance instillations
(one instillation every 4–8 weeks). Schedules slightly
differed per centre.
Analyses
For demographics, means with standard deviations
(SD) or standard error of the mean (SEM) were cal-
culated for continuous variables. For dichotomous
variables, percentages were determined.
Complete response was assessed and addition-
ally compared between BCG-unresponsive, other
BCG-treated, and treatment naı¨ve patients using
the chi-square test. Absolute recurrence rates were
assessed. Kaplan-Meier analysis with Mantel-Cox
log rank tests was used for the recurrence-free, overall
and cystectomy-free survival evaluation. Addition-
ally, relative survival was determined, defined as the
ratio of overall survival of the patients by the sur-
vival of a similar general Dutch population matched
on age, sex and calendar year and can be used as an
approximation of cancer-specific survival.
Analyses were performed using SPSS software,
version 22, with a two-sided p < 0.05 considered sta-
tistically significant. For the relative survival analysis,
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA)
was used.
RESULTS
Patients
In total, 270 CIS patients treated with RF-
CHT were identified. Of these, 236 patients had
received≥6 RF-CHT instillations, whereas pathol-
ogy or cystoscopy and cytology results at 6 months
of follow-up were available in 150 patients. Exclu-
sion of the 86 patients was solely based on this
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Table 1
Demographics
Overall BCG- Other BCG- Treatment naı¨ve
CIS unresponsive CIS treated CIS CIS
n 150 50 46 missing n = 4 47 missing n = 3
Sex
Male n (%) 123 (82.0) 38 (76.0) 39 (84.8) 40 (85.1)
Female n (%) 27 (18.0) 12 (24.0) 7 (15.2) 7 (14.9)
Mean age at start of RF-CHT y (SD) 69.4 (9.52) 69.4 (9.84) 72.2 (9.00) 67.2 (9.08)
General history n (%)
BPH 25 (16.7) 7 (14.0) 9 (19.6) 9 (19.1)
Prostate cancer 14 (9.3) 4 (8.0) 7 (15.2) 3 (6.4)
Urethral stricture 4 (2.6) 0 (0.0) 2 (4.3) 2 (4.3)
Bladder diverticulum 2 (1.3) 1 (2.0) 1 (2.2) 0 (0.0)
Worst stage in NMIBC history† n (%)
Ta 11 (7.3) 3 (6.0) 4 (8.7) 4 (8.5)
T1 24 (16.0) 4 (8.0) 7 (15.2) 13 (27.7)
CIS 63 (42.0) 28 (56.0) 14 (30.4) 18 (38.3)
Ta + CIS 20 (13.3) 8 (16.0) 8 (17.4) 2 (4.3)
T1 + CIS 32 (21.3) 7 (14.0) 13 (28.3) 10 (21.3)
Worst grade in NMIBC history† n (%)
G1 7 (4.7) 3 (6.0) 1 (2.2) 3 (6.4)
G2 8 (5.3) 2 (4.0) 1 (2.2) 4 (8.5)
G3 135 (90.0) 45 (90.0) 44 (95.7) 40 (85.1)
Pathology before start of RF-CHT n (%)
CIS only 89 (59.3) 39 (78.0) 20 (43.5) 27 (57.4)
CIS + TaLG 7 (4.7) 1 (2.0) 3 (6.5) 2 (4.3)
CIS + TaHG 20 (13.3) 6 (12.0) 10 (21.7) 3 (6.4)
CIS + T1LG 1 (0.7) 1 (2.0) 0 (0.0) 0 (0.0)
CIS + T1HG 33 (22.0) 3 (6.0) 13 (28.3) 15 (31.9)
BCG instillations before RF-CHT mean (SEM)* 9.1 (0.76) 17.5 (0.94) 9.2 (0.98) N/A N/A
TURBTs before RF-CHT mean (SEM) 2.3 (0.10) 2.6 (0.15) 2.4 (0.16) 2.1 (0.16)
RF-CHT instillations at CR evaluation mean (SEM)‡∗ 8.2 (0.13) 7.6 (0.15) 8.8 (0.20) 8.0 (0.28)
BCG, bacille Calmette-Gue´rin; BPH, benign prostate hypertrophia; CIS, carcinoma in-situ; CR, complete response; HG, high grade; LG,
low grade; N/A, not applicable; NMIBC, non-muscle invasive bladder cancer; RF-CHT, radiofrequency-induced chemohyperthermia; SD,
standard deviation; SEM, standard error of the mean; TURBT, trans-urethral resection of bladder tumor or biopsies. *Values differ significantly
between each group. †Excluding the pathology stage or grade for which RF-CHT was started. ‡Calculation for 6-months CR evaluation
(range 5–9 months). For CR evaluation after additional maintenance RF-CHT instillations, the mean amount of instillations was 10.3 (SEM
0.20), 9.8 (SEM 0.27), 10.0 (0.25), and 11.0 (SEM 0.43), respectively, and did not differ significantly between groups.
criterion. Patient demographics of the included group
of patients (n = 150) – which were used for the
efficacy analysis – are depicted in Table 1, and
were similar to the total group of patients who
had received≥6 RF-CHT instillations. Mean age
was 69.4 years, with a male-to-female ratio of 4.6
to 1. Patients received an average of 9.1 previous
BCG-instillations and were treated with a mean of
8.2 RF-CHT instillations at CR assessment, with a
dose of twice 40 mg (n = 119, 79.3%) or, less fre-
quently, twice 20 mg MMC (n = 31, 20.7%). Of all
150 patients, 76.7% had recurrent CIS with or with-
out concomitant papillary tumor as a worst stage in
their history, whereas the other 23.3% of patients had
primary CIS.
The mean time of follow-up for the overall group
(n = 150), BCG-unresponsive patients (n = 50), other
BCG-treated patients (n = 46, missing n = 4), and
treatment naı¨ve patients (n = 47, missing n = 3) was
35.8 months, 27.5 months, 38.5 months, and 40.6
months, respectively.
Efﬁcacy
CR after 6 months was 66.2% (Table 2). For BCG-
unresponsive patients the CR was 46.0%, which
differed significantly from other BCG-treated and
treatment naı¨ve CIS patients (71.7% and 83.0%
respectively, p < 0.001). In patients with a CR, the
subsequent recurrence rate and RFS after 2 years
of follow-up were 18.8% and 74.5% for the overall
group and did not differ significantly between any of
the groups (Table 2, Fig. 1). CR rate increased with
an increased number of RF-CHT instillations from
66.2% to 77.1% for the overall group after respec-
tively a mean amount of 8.2 and 10.3 instillations. For
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Table 2
Complete response rates at 6 months from start of RF-CHT with corresponding 2-year recurrence rates and recurrence free survival
Overall BCG- Other BCG- Treatment naı¨ve
CIS unresponsive CIS treated CIS CIS
n 143 (missing n = 7) 50 46 (missing n = 4) 47 (missing n = 3)
CR at 6 months from start
RF-CHT n (%)
96 (66.2) 23 (46.0)* 33 (71.7)* 39 (83.0)*
2-year recurrence rate n (% of
patients with CR)
18 (18.8) 4 (17.4) 9 (27.3) 5 (12.8)
2-year RFS cumulative surviving
proportion in %
74.5 68.9 68.6 83.6
BCG, bacille Calmette-Gue´rin; CIS, carcinoma in-situ; CR, complete response; RF-CHT, radiofrequency-induced chemohyperthermia; RFS,
recurrence free survival. *significant difference between BCG-unresponsive, other BCG-treated, and treatment naı¨ve CIS patients, p < 0.001.
Fig. 1. Recurrence-free survival after RF-CHT split by treatment history. No significant difference between BCG-unresponsive, other BCG-
treated, and treatment naı¨ve CIS patients was observed, p = 0.08. BCG, bacillus Calmette-Gue´rin; CIS, carcinoma in situ; CR, complete
response; RF-CHT, radiofrequency-induced chemohyperthermia.
BCG-unresponsive patients, CR rate increased from
46.0% to 57.6% after a mean amount of 7.6 and 9.8
instillations, respectively (Table 3). Patients treated
with a dose of 40 mg had a trend towards higher CR
rates compared with a dose of 20 mg, although not
significant (69.5% vs. 51.6%, p = 0.06).
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Table 3
Complete response rates after additional maintenance instillations with corresponding 2-year recurrence rates and recurrence free survival
Overall BCG- Other BCG- Treatment naı¨ve
CIS unresponsive CIS treated CIS CIS
n† 131 33 57 41
CR after additional maintenance
instillations‡ n (%)
101 (77.1) 19 (57.6)* 45 (78.9)* 37 (90.2)*
2-year recurrence rate n (% of patients with
CR)
20 (19.4) 5 (26.3) 10 (22.2) 5 (13.5)
2-year RFS cumulative surviving proportion
in %
75.2 59.9 73.7 82.8
BCG, bacille Calmette-Gue´rin; CIS, carcinoma in-situ; CR, complete response; RF-CHT, radiofrequency-induced chemohyperthermia; RFS,
recurrence free survival. †The n differs with the CR assessment at 6 months calculation due to missing data on CR in the different groups.
‡On average, an additional amount of two RF-CHT instillations had been received as compared to the CR assessment at 6 months from
start of RF-CHT. Patient group was not identical to the CR group at 6 months. ∗significant difference between BCG-unresponsive, other
BCG-treated, and treatment naı¨ve CIS patients, p = 0.002.
In 13.3% of patients, progression to MIBC with
or without lymph node or distant metastasis at
final follow-up was seen, consisting of 16.0% in
BCG-unresponsive, 13.0% in other BCG-treated, and
10.6% in treatment naı¨ve CIS patients (p = 0.74).
The bladder preservation rate at final follow-
up was 78.5% with a mean cystectomy-free time
of 99.9 months (95%-CI 86.7–113.1). For BCG-
unresponsive patients these were 71.4% and 45.2
months (95%-CI 35.7–54.7), respectively, and dif-
fered significantly between BCG-unresponsive and
both other BCG-treated and treatment naı¨ve patients
(p = 0.006, Fig. 2, Table 4).
Patients had an overall survival of 78.0% at
final follow-up (Table 4). The mean survival time
was 89.5 months (95%-CI 74.7–104.8). For BCG-
unresponsive patients these were 76.0% and 79.7
months (95%-CI 65.2–94.3), respectively (Fig. 3).
No statistical difference between the groups was
found, although a trend towards a significant dif-
ference between other BCG-treated and treatment
naı¨ve patients was observed (p = 0.06). The relative
survival, acting as an approximation of the cancer-
specific survival, was 89% after 3 years and 84% after
5 years of follow-up, although 95% confidence inter-
vals overlapped substantially between the actually
observed overall survival and the relative survival.
For Dutch patients only, relative survival was 82%
after 3 years and 86% after 5 years of follow-up
(Fig. 4).
If CIS patients who had at least six RF-CHT
instillations were used for the efficacy analysis
(n = 236), thus abandoning the more strict inclu-
sion criterion of either pathology or cystoscopy
plus cytology availability at follow-up, progres-
sion rate, cystectomy-free rate, and overall survival
rate did not substantially differ from the group
analyzed above. This analysis thus confirms that
our data are consistent also within a broader inclu-
sion of patients and unlikely subject to significant
selection bias.
Treatment tolerability
In total, 13.4% and 17.8% of patients receiving
any amount of RF-CHT instillations eventually had
to stop either induction or maintenance RF-CHT
instillations due to adverse events. Pooled for both
induction and maintenance, these adverse events con-
sisted of pain or spasms during an instillation in 7.8%,
allergy in 8.2%, and frequency or urge between instil-
lations in 7.5% of total patients.
DISCUSSION
CIS is at risk for progression to muscle-invasive
disease. In cases not responding or intolerant to
BCG immunotherapy, urological guidelines advise a
radical cystectomy. Due to its associated morbidity
and mortality, alternatives to radical cystectomy are
desired in CIS patients who no longer respond to or
tolerate BCG instillations. Indeed, even in BCG naı¨ve
intermediate to high-risk NMIBC, such an alterna-
tive might be of value in light of BCG toxicity and
availability.
We found that with intravesical RF-CHT, a
complete response rate of 66.2% with subsequent
recurrences in 18.8% after 2 years can be achieved
in CIS patients. A higher amount of RF-CHT
instillations further improved these figures. More
interestingly, a bladder preservation rate of 78.5%
after a mean follow-up of about 3 years with a 13.3%
rate of disease progression was found. Also for BCG-
unresponsive patients – who are at the highest risk of
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Fig. 2. Cystectomy-free survival split by treatment history. A significant difference between BCG-unresponsive, other BCG-treated, and
treatment naı¨ve CIS patients was observed, p = 0.006. BCG, bacillus Calmette-Gue´rin; CIS, carcinoma in situ; RF-CHT, radiofrequency-
induced chemohyperthermia.
Table 4
Bladder preservation and overall survival rate
Overall BCG- Other BCG- Treatment naı¨ve
CIS† unresponsive CIS‡ treated CIS§ CIS¶
n 144 (missing n = 6) 49 (missing n = 1) 44 (missing n = 6) 45 (missing n = 5)
Bladder preservation
rate n (%)
113 (78.5) 35 (71.4)* 37 (84.1)* 39 (86.7)*
n 150 50 46 (missing n = 4) 47 (missing n = 3)
Overall survival n (%) 117 (78.0) 38 (76.0) 32 (69.6)** 41 (87.2)**
BCG, bacille Calmette-Gue´rin; CIS, carcinoma in-situ; RF-CHT, radiofrequency-induced chemohyperthermia; SEM, standard error of the
mean. †mean follow-up of 35.8 months, SEM 2.18. ‡mean follow-up of 27.5 months, SEM 3.01. §mean follow-up of 38.5 months, SEM 3.67.
¶mean follow-up of 40.6 months, SEM 4.47. *significant difference between BCG-unresponsive and both other BCG-treated and treatment
naı¨ve CIS patients, p = 0.006. **trend towards a significant difference between other BCG-treated and treatment naı¨ve CIS patients, p = 0.06.
progression – a promising bladder preservation rate
of 71.4% and a disease progression rate of 16.0%
was found. Thus, RF-CHT might prove to be an
option in patients who are at high risk of progres-
sion and unwilling or unable to undergo a radical
cystectomy.
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Fig. 3. Observed overall survival split by treatment history. A trend towards a significant difference between other BCG-treated and treatment
naı¨ve CIS patients was observed, p = 0.06. BCG, bacillus Calmette-Gue´rin; CIS, carcinoma in situ; RF-CHT, radiofrequency-induced
chemohyperthermia.
Although the current gold standard for CIS, i.e.
BCG immunotherapy, has proven to be effective
in high-risk NMIBC, a substantial amount of
patients recur, progress, or appear intolerant for
BCG [12–15]. For these patients, several alternative
options to radical cystectomy are being investigated.
Electromotive drug administration, in which uptake
of MMC is enhanced by electrical facilitation of
osmosis, has shown promising results combined with
BCG vs. BCG alone, but has yet only been described
in BCG-naı¨ve T1 patients after transurethral resec-
tion and not in BCG-unresponsive CIS patients [23].
Other options under research include photodynamic
therapy which uses photo-activation of a cytotoxic
agent targeted to tumor cells, chemotherapeutic
agents other than the typically administered drugs
like mitomycin C and epirubicin [24–28], or combi-
nations of chemotherapeutic drugs (NCT02202772).
None have yet shown sufficient efficacy to replace
BCG. In future trials, a specific interest in using
cytokines (NCT02773849), PD-(L)1 inhibitors
(NCT02844816, NCT02625961), and device-
assisted therapies (e.g. RF-CHT, NCT03335059) is
seen. To date, the most promising results in NMIBC
have been achieved using RF-CHT [18, 19, 29].
This study demonstrates that RF-CHT might be a
useful treatment option for patients unfit or unwill-
ing to undergo a radical cystectomy. Apart from the
good CR rate and subsequent low recurrence rate,
the progression rate for overall and, in particular,
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Fig. 4. Survival relative to a matched general Dutch population. Survival for a) all patients (n = 150), and b) Dutch patients only (n = 58).
Vertical bars represent 95% confidence intervals. RF-CHT, radiofrequency-induced chemohyperthermia.
BCG-unresponsive CIS patients of 13.3% and 16.0%
after up to nearly 36 months compares favorable
to progression rates in similar high-risk groups as
reported by the CUETO group [13, 14]. Most interest-
ingly, however, is the accomplished cystectomy-free
rate of 78.5%. In this group of high-risk patients, AUA
and EAU guidelines advise a radical cystectomy in all
patients fit enough for major surgery [7, 8]. Thus, an
important finding of this alternative treatment option
is the potential avoidance, or at least delay, of a cys-
tectomy in a majority of these patients.
In addition, we found an overall absolute sur-
vival of about 71% at 5 years of follow-up (Fig. 3).
The relative survival after 5 years is about 53% for
all stage bladder cancer [30] and 88% for NMIBC
only[source: Netherlands Cancer Registry] in Dutch
bladder cancer patients. For Europe in general, the
relative survival is about 68% and 88% for all stage
disease and NMIBC only, respectively [31]. In this
light, the relative 5-year survival of 84% in our high-
risk patient cohort seemed relatively good.
Of interest is the trend towards a lower OS in other
BCG-treated patients vs. treatment naı¨ve patients.
This possibly is explained by the BCG-intolerant
patients in this group, who might have been more
frail or might have stopped BCG more often due to
comorbidity.
Although BCG-unresponsive patients had signifi-
cantly worse CR (46.0%, p < 0.001) and cystectomy-
free rates (71.4%, p = 0.006), OS did not differ
significantly compared with the other groups. More-
over, the CR, RFS, and cystectomy-free rates still
seem higher compared with other conservative thera-
peutic options [32] and fulfill the minimum criterion
of a 30% RFS at 18 to 24 months as defined by
the Food and Drug Administration and AUA for
BCG-unresponsive high risk NMIBC [21]. These
results reflect a substantial gain in this patient group.
One study which has previously evaluated RF-
CHT in CIS patients, showed better 3-months CR
rates of 92% with 49% having a recurrence and 13%
undergoing a cystectomy at a mean follow-up of
27 months [20]. However, this patient group was
somewhat smaller (n = 49) and consisted of fewer
BCG-treated patients (n = 34) of which only 17 were
BCG-refractory. Another study on RF-CHT evalu-
ated a group of patients of whom 83% had CIS,
and 80% of patients were previously treated with
BCG, without further information on BCG-response.
After 8 weeks, a CR rate in CIS patients of 80%
was found [33]. A similar rate was observed in a
recent randomized controlled trial comparing BCG-
naı¨ve patients treated with BCG vs. RF-CHT [19].
Although CR and RFS rates found in this study are
lower, we have evaluated patients who likely were at
higher risk for recurrence or progression considering
two-thirds were BCG-failures or intolerant, possibly
explaining the different CR rates. Moreover, the CR-
rate was evaluated at 6 months in our study instead of
at≤3 months of follow-up. To our best knowledge, no
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additional studies have investigated RF-CHT effect in
CIS patients.
Compared to BCG alone, our reported CR rates at 6
months after RF-CHT and the associated recurrence
rates are at the better end of the literature-reported
range after BCG in treatment naı¨ve CIS patients, with
the CR rate ranging from 65–77% at 3–5 months and
recurrence rates varying up to 30% [34, 35].
In considering RF-CHT as an alternative to
surgery, one should take the risks of potential under-
treatment with RF-CHT vs. the impact on quality of
life after radical cystectomy into account [28]. The
significant morbidity and mortality associated with
a radical cystectomy combined with its functional
consequences is for many patients the main reason
to opt for conservative management. However, 13%
and 18% of the studied patients eventually had to stop
either induction or maintenance RF-CHT instillations
due to adverse events, consisting of pain, urgency,
frequency and allergic reactions. In comparison to
BCG, RF-CHT seems to have a similar quantity of
AEs, although the type of AEs differ [19].
Due to the retrospective nature, some limitations to
this study exist. The collected data was highly hetero-
geneous due to randomly missing values and different
standards of treatment and follow-up between the
participating centres. Despite missing values, the dif-
ferent groups had comparable demographic data. To
overcome different disease management per centre,
strict definitions were applied to improve reliability
and assess results objectively. As a downside, a sub-
stantial proportion of the selected patients needed to
be excluded from analysis inducing risk of selection
bias. Moreover, by setting pathology or combined
cystoscopy plus cytology availability as a precondi-
tion to analysis, a bias towards higher tumor rates
or non-response was created: if solely a cystoscopy
or cytology only – showing a negative result – was
performed, the patient was excluded from analysis
even though it is likely that no significant tumor
(i.e.>TaLG) was present. If, on the other hand, a pos-
itive result with solely cystoscopy or cytology was
found, additional evaluation was performed and the
patient – who had a higher likelihood of tumor pres-
ence – was included. Therefore, the results presented
in this paper might depict a worst-case scenario.
In addition, either pathology or the combination
of cystoscopy and cytology was also used to assess
the 2-year recurrence rate. Since specificity for cytol-
ogy and cystoscopy is higher than its sensitivity, the
amount of false negative cases is limited whereas the
amount of false positive cases might be high [36, 37].
Again, this might have resulted in a higher amount of
observed recurrences than the actual amount of recur-
rences, although most recurrences in our study were
pathology-confirmed (17/18). Lastly, since this study
was non-randomized, a selection bias with confound-
ing by indication to treat may be present even though
analysis of all patients with≥6 RF-CHT instillations
did not yield substantially different results.
CONCLUSIONS
Intravesical radiofrequency-induced chemohyper-
thermia showed good results in CIS patients – even if
BCG-unresponsive – and avoided radical cystectomy
in 78.5% of cases for at least 3 years with a modest
risk of progression. Thus, RF-CHT might prove to be
an alternative to cystectomy in selected patients, even
in this cohort at high risk of disease progression. Con-
sequently, further comparison of RF-CHT with other
techniques of chemohyperthermia and with different
bladder-sparing approaches is of great interest.
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